Under the agreement, Cytyc of Marlborough said today it will make an initial upfront cash payment of $60 million plus additional milestone payments to buy the privately held California company.
Cytyc's products cover a range of cancer and women's health applications, including cervical cancer screening, treatment of excessive menstrual bleeding, and radiation treatment of early-stage breast cancer.
Adiana has developed a non-incisional alternative to tubal ligation for permanent contraception in women.
Adiana's contraceptive technique "offers remarkable synergies with Cytyc's existing products directed at the OBGYN physician," Cytyc chairman and chief executive Patrick J. Sullivan said in a statement.
(By Chris Reidy, Globe staff)